Healthcare Industry News: Fibromyalgia
News Release - March 13, 2014
Dolphin Neurostim Receives CE Approval for European Distribution
FDA Approved Device Provides Pain Relief where Other Modalities FailJacksonville, FL -- (Healthcare Sales & Marketing Network) -- With more than 1 in 7 people living suffering from chronic pain, the Dolphin Neurostim, a huge success in North America, is now poised to assist Europeans for their treatment of chronic pain.
The Dolphin Neurostim is a hand-held, portable microcurrent device that is designed for both professional and at home use. The Dolphin Neurostim is different from traditional TENS devices. The Dolphin Neurostim applies concentrated DC microcurrent stimulation, whereas conventional TENS applies dispersed AC current via pads. Dolphin’s Stimulation releases fascia, muscle tonicity, and endorphins. This multi-pronged approach the key reason why the Dolphin Neurostim is so effective in managing pain.
Dolphin has received exceptionally positive feedback throughout North America. Portable, versatile & highly effective, independent Florida Hospital research comparing TENS to Dolphin showed that the Dolphin Neurostim produces significantly greater reduction in pain (83% vs 48%) than TENS.
The Dolphin Neurostim has been used to effectively treat: Fibromyalgia, back pain, sciatica, migraines, neuropathies (see a video testimonial of diabetic neuropathy patient here: http://youtu.be/UitpHEze2Zc), along with neck, hip & shoulder pains & much more! The Dolphin Neurostim is patient friendly and ideal for the patient home setting; easy-to-apply, requiring only minutes for a full treatment & very safe to use. Pain relief can last from days to weeks from a single application.
The Dolphin Neurostim device is accompanied by 150 page protocol manual and toll-free support line; it retails for $429.00 and comes with a 30 day money-back guarantee. Distributors are welcome.
For more information call: Acumed Medical 1-800-567-PAIN (7246)
www.DolphinNeurostim.com
Source: Acumed Medical Ltd
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
